Therapy News and Research

RSS

Newborn screening indicates that incidence of SCID is higher than previously believed

Newborn screening performed in numerous states indicates that the incidence of the potentially life-threatening disorder, severe combined immunodeficiency, is higher than previously believed, at 1 in 58,000 births, although there is a high rate of survival, according to a study in the August 20 issue of JAMA.

20 Aug 2014

Researchers find current blood pressure recommendations for older patients

Confused about the new blood pressure recommendations and what you should be aiming for? You're not alone.

20 Aug 2014

Perampanel does not offer added benefit for patients with Epilepsy

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures).

20 Aug 2014

Research validates Myc inhibition as effective therapeutic strategy for glioma

Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.

19 Aug 2014

Rettsyndrome.Org awards $1.5M to advance translational research, support Neuro-Habilitation Program

The International Rett Syndrome Foundation now doing business as Rettsyndrome.org announces today that the Board of Trustees has awarded $1.5M to support 10 new grants to further translational research and launch of the neuro-habilitation therapeutic program, and fund clinical research.

19 Aug 2014

Penn researchers analyze clinical practice guidelines

The common thought in the medical community is that the randomized, controlled trial is the gold standard in medical research.

19 Aug 2014

New model shows how faculty development programs can affect institutional behaviors

Methods used to demonstrate the impact of faculty development programs have long been lacking.

19 Aug 2014

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs.

19 Aug 2014

University of Kansas researcher earns grant to study role of dietary supplement in muscle growth

A University of Kansas professor has been chosen to take part in a grant project that will test the role of a dietary supplement in muscle growth for everyone from athletes to the elderly and has also been named educator of the year by the granting agency.

19 Aug 2014

Natural killer cells can be used to combat acute lymphoblastic leukemia

Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that can be used to destroy the cancer cells.

19 Aug 2014

Mount Sinai researchers receive federal funding to treat HCV in primary care settings

With the number of people with chronic hepatitis C reaching record levels in New York City and the recent availability of more effective treatments, researchers from the Icahn School of Medicine at Mount Sinai recently announced the receipt of $1.9 million in federal funding to increase its capacity to treat HCV in primary care settings.

19 Aug 2014

Implantable heart devices provide same substantial survival benefit, regardless of race

Racial and ethnic minorities who receive implantable devices to treat heart failure derive the same substantial survival benefit from these therapies as white patients, new UCLA-led research shows.

19 Aug 2014

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.

19 Aug 2014

FGF proteins play broad roles in wound healing

Mice missing two important proteins of the vascular system develop normally and appear healthy in adulthood, as long as they don't become injured. If they do, their wounds don't heal properly, a new study shows.

19 Aug 2014

UC Santa Cruz cancer researcher receives $350,000 to develop novel drugs for breast cancer

UC Santa Cruz cancer researcher Seth Rubin has received a $350,000 grant to fund his work toward the development of a new class of drugs for treating breast cancer. The grant is a Breast Cancer Research Program Breakthrough Award from the congressionally directed medical research programs of the U.S. Department of Defense.

19 Aug 2014

Queen's University scientists make breakthrough in fight against hospital superbugs

Scientists at Queen's University Belfast have made a breakthrough in the fight against the most resistant hospital superbugs.

19 Aug 2014

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.

19 Aug 2014

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir Biosciences, Inc., a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration approved drugs, through an established compassionate use regulatory pathway.

19 Aug 2014

Study reveals treatment trends for prostate cancer in Japan

There has been a recent increase in use of radiotherapy in Japanese men newly diagnosed with prostate cancer and a concomitant decrease in use of androgen deprivation therapy, study findings indicate.

18 Aug 2014

Dopamine therapy linked to increased impulse control disorders, daytime sleepiness in early PD patients

New Penn Medicine research shows that neuropsychiatric symptoms such as depression, anxiety and fatigue are more common in newly diagnosed Parkinson's disease (PD) patients compared to the general population.

18 Aug 2014

Therapy News and Research

Newborn screening indicates that incidence of SCID is higher than previously believed

Researchers find current blood pressure recommendations for older patients

Perampanel does not offer added benefit for patients with Epilepsy

Research validates Myc inhibition as effective therapeutic strategy for glioma

Rettsyndrome.Org awards $1.5M to advance translational research, support Neuro-Habilitation Program

Penn researchers analyze clinical practice guidelines

New model shows how faculty development programs can affect institutional behaviors

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

University of Kansas researcher earns grant to study role of dietary supplement in muscle growth

Natural killer cells can be used to combat acute lymphoblastic leukemia

Mount Sinai researchers receive federal funding to treat HCV in primary care settings

Implantable heart devices provide same substantial survival benefit, regardless of race

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

FGF proteins play broad roles in wound healing

UC Santa Cruz cancer researcher receives $350,000 to develop novel drugs for breast cancer

Queen's University scientists make breakthrough in fight against hospital superbugs

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Study reveals treatment trends for prostate cancer in Japan

Dopamine therapy linked to increased impulse control disorders, daytime sleepiness in early PD patients

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News